%0 Journal Article
%@ 2561-326X
%I JMIR Publications
%V 2
%N 2
%P e24
%T The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing
%A Lo,Louisa L
%A Collins,Ian M
%A Bressel,Mathias
%A Butow,Phyllis
%A Emery,Jon
%A Keogh,Louise
%A Weideman,Prue
%A Steel,Emma
%A Hopper,John L
%A Trainer,Alison H
%A Mann,Gregory B
%A Bickerstaffe,Adrian
%A Antoniou,Antonis C
%A Cuzick,Jack
%A Phillips,Kelly-Anne
%+ Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Victoria, 8006, Australia, 61 3 85597860, Kelly.Phillips@petermac.org
%K clinical decision support
%K breast cancer
%K BRCA1 gene
%K BRCA2 gene
%K risk
%K preventive health
%K screening
%D 2018
%7 07.11.2018
%9 Original Paper
%J JMIR Formativ Res
%G English
%X Background: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. Objective: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. Methods: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. Results: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. Conclusions: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent. 
%M 30684421
%R 10.2196/formative.9935
%U http://formative.jmir.org/2018/2/e24/
%U https://doi.org/10.2196/formative.9935
%U http://www.ncbi.nlm.nih.gov/pubmed/30684421